IceCure Medical (NASDAQ:ICCM - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $2.50 target price on the stock. HC Wainwright's price objective indicates a potential upside of 141.55% from the company's current price.
IceCure Medical Stock Down 1.4%
Shares of NASDAQ ICCM traded down $0.02 during midday trading on Thursday, hitting $1.04. The stock had a trading volume of 79,451 shares, compared to its average volume of 474,252. The business's 50 day moving average is $1.11 and its 200-day moving average is $1.15. IceCure Medical has a 52 week low of $0.48 and a 52 week high of $1.66. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The company has a market cap of $57.44 million, a P/E ratio of -3.57 and a beta of 0.41.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last released its quarterly earnings data on Wednesday, May 28th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The business had revenue of $0.73 million for the quarter, compared to analysts' expectations of $0.75 million. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. During the same period in the prior year, the firm posted ($0.08) EPS. As a group, analysts predict that IceCure Medical will post -0.28 EPS for the current year.
Institutional Trading of IceCure Medical
An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC raised its stake in shares of IceCure Medical Ltd (NASDAQ:ICCM - Free Report) by 58.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,453 shares of the company's stock after buying an additional 14,893 shares during the quarter. Geode Capital Management LLC owned about 0.07% of IceCure Medical worth $44,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 0.62% of the stock is currently owned by institutional investors and hedge funds.
IceCure Medical Company Profile
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Further Reading
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
